Skip to main content
SpringerLink
Log in

CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis

  • Published:
Journal of Huazhong University of Science and Technology [Medical Sciences] Aims and scope Submit manuscript

Summary

Several studies have investigated the association between CYP2C19 polymorphism and clinical outcomes of patients treated with clopidogrel, but few have noticed the difference in association between Westerners and Asians. We searched MEDLINE, EMBASE and Cochrane Library database and conducted a systematic review and meta-analysis. Thirty-six studies involving 44 655 patients with coronary artery disease (CAD) treated with clopidogrel were included, of which more than 68% had undergone percutaneous coronary intervention (PCI). The primary outcome of our interest was the recurrence of major adverse cardiovascular events (MACE) in those CAD patients. Firstly, we found that the distribution of reduced-function CYP2C19 allele varied between Westerners and Asians. Among Asians, 1 and 2 reduced-function CYP2C19 mutant allele carriers accounted for 42.5% and 10%, respectively. While among Westerners, 1 and 2 reduced-function CYP2C19 mutant allele carriers accounted for 25.5% and 2.4%, respectively. Secondly, the impact of CYP2C19 polymorphism on clinical outcomes of patients treated with clopidogrel varied with races. Among Asians, only 2 reduced-function CYP2C19 mutant allele carriers had the reduced effect of clopidogrel. And the reduced effect was significant only after the 30th day of treatment. While among Westerners, both 1 and 2 reduced-function CYP2C19 allele carriers had the reduced effect, and it mainly occurred within the first 30 days. Thirdly, the safety of clopidogrel was almost the same among races. Reduced-function allele non-carriers had higher risk for total bleeding but did not have higher risk for major bleeding. It is suggested that CYP2C19 polymorphism affects the efficacy of clopidogrel differently among Westerners and Asians.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Snoep JD, Hovens MM, Eikenboom JC, et al. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J, 2007,154(2):221–231

    Article  CAS  PubMed  Google Scholar 

  2. Food U. Drug Administration. FDA Drug Safety Communication: Reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. FDA, 2010

    Google Scholar 

  3. Pare G, Mehta SR, Yusuf S, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med, 2010,363(18):1704–1714

    Article  CAS  PubMed  Google Scholar 

  4. Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet, 2010,376(9749):1320–1328

    Article  CAS  PubMed  Google Scholar 

  5. Liang ZY, Han YL, Zhang XL, et al. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. EuroIntervention, 2013,9(3):316–327

    Article  PubMed  Google Scholar 

  6. Nishio R, Shinke T, Otake H, et al. Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in japanese patients receiving clopidogrel. Circ J, 2012,76(10):2348–2355

    Article  CAS  PubMed  Google Scholar 

  7. Oh IY, Park KW, Kang SH, et al. Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. Heart, 2012,98(2):39–144

    Article  Google Scholar 

  8. Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J, 2011,75(1):99–105

    Article  CAS  PubMed  Google Scholar 

  9. Bauer T, Bouman HJ, van Werkum JW, et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ, 2011,4(343):d4588

    Article  Google Scholar 

  10. Holmes MV, Perel P, Shah T, et al. CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis. JAMA, 2011, 306(24):2704–2714

    Article  CAS  PubMed  Google Scholar 

  11. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol, 2010,56(2):134–143

    Article  CAS  PubMed  Google Scholar 

  12. Jang JS, Cho KI, Jin HY, et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol, 2012,110(4):502–508

    Article  CAS  PubMed  Google Scholar 

  13. Jin B, Ni HC, Shen W, et al. Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel. Mol Biol Rep, 2011,38(3):1697–1702

    Article  CAS  PubMed  Google Scholar 

  14. Liu YP, Hao PP, Zhang MX, et al. Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis. Thromb Res, 2011,128(6):593–594

    Article  CAS  PubMed  Google Scholar 

  15. Mao L, Jian C, Changzhi L, et al. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Arch Cardiovasc Dis, 2013,106(10):517–527

    Article  PubMed  Google Scholar 

  16. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA, 2010,304(16):1821–1830

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Sofi F, Giusti B, Marcucci R, et al. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J, 2011,11(3):199–206

    Article  CAS  PubMed  Google Scholar 

  18. Sorich MJ, Polasek TM, Wiese MD. Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding. Thromb Haemost, 2012,108(1):199–200

    Article  CAS  PubMed  Google Scholar 

  19. Zabalza M, Subirana I, Sala J, et al. Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel. Heart, 2012,98(2):100–108

    Article  CAS  PubMed  Google Scholar 

  20. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA, 2000,283(15):2008–2012

    Article  CAS  PubMed  Google Scholar 

  21. Mega JL, Simon T, Collet J-P, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA, 2010,304(16):1821–1830

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Man M, Farmen M, Dumaual C, et al. Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans. J Clin Pharmacol, 2010,50(8):929–940

    Article  CAS  PubMed  Google Scholar 

  23. Scott S, Sangkuhl K, Gardner E, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther, 2011,90(2):328–332

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Kang YH, Lao HY, Wu H, et al. Association of PON1 genotype and haplotype with susceptibility to coronary artery disease and clinical outcomes in dual antiplatelet-treated Han Chinese patients. Eur J Clin Pharmacol, 2013,69(8):1511–1519

    Article  CAS  PubMed  Google Scholar 

  25. Collet JP, Hulot JS, Pena A, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet, 2009,373(9660):309–317

    Article  CAS  PubMed  Google Scholar 

  26. Bhatt DL, Paré G, Eikelboom JW, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J, 2012,33(17):2143–2150

    Article  CAS  PubMed  Google Scholar 

  27. Harmsze AM, van Werkum JW, Ten Berg JM, et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J, 2010,31(24):3046–3053

    Article  CAS  PubMed  Google Scholar 

  28. Luo Y, Zhao Y, Verdo A, et al. Relationship between cytochrome P450 2C19* 2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel. J Int Med Res, 2011,39(5):2012–2019

    Article  CAS  PubMed  Google Scholar 

  29. Liu Y, Liu N, Li W, et al. Relationship of CYP2C19*2 and CYP2C19*3 gene polymorphism with clopidogrel response variability and recurrent cardiovascular events in Chinese patients undergoing percutaneous coronary intervention. Pharmacology, 2013,91(3–4):165–172

    Article  CAS  PubMed  Google Scholar 

  30. Malek LA, Kisiel B, Spiewak M, et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J, 2008,72(7):1165–1169

    Article  CAS  PubMed  Google Scholar 

  31. Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J, 2009,30(8):916–922

    Article  CAS  PubMed  Google Scholar 

  32. Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med, 2009,360(4):363–375

    Article  CAS  PubMed  Google Scholar 

  33. Wu H, Qian J, Xu J, et al. Effects of CYP2C19 variant alleles on postclopidogrel platelet reactivity and clinical outcomes in an actual clinical setting in China. Pharmacogenet Genomics, 2012,22(12):887–890

    Article  CAS  PubMed  Google Scholar 

  34. Yamamoto K, Hokimoto S, Chitose T, et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol, 2011,57(2):194–201

    Article  PubMed  Google Scholar 

  35. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med, 2009,360(4):354–362

    Article  CAS  PubMed  Google Scholar 

  36. Anderson CD, Biffi A, Greenberg SM, et al. Personalized approaches to clopidogrel therapy: are we there yet? Stroke, 2010,41(12):2997–3002

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Harmsze AM, van Werkum JW, Hackeng CM, et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics, 2012,22(3):169–175

    Article  CAS  PubMed  Google Scholar 

  38. Harmsze AM, van Werkum JW, Souverein PC, et al. Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost, 2011,9(10):1892–1901

    Article  CAS  PubMed  Google Scholar 

  39. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials a case for standardized definitions. Circulation, 2007,115(17):2344–2351

    Article  PubMed  Google Scholar 

  40. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol, 2011,57(25):2474–2483

    Article  CAS  PubMed  Google Scholar 

  41. Giusti B, Gori AM, Marcucci R, et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol, 2009,103(6):806–811

    Article  CAS  PubMed  Google Scholar 

  42. Malek LA, Przyluski J, Spiewak M, et al. Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction. Cardiology, 2010,117(2):81–87

    Article  CAS  PubMed  Google Scholar 

  43. Tiroch KA, Sibbing D, Koch W, et al. Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J, 2010,160(3):506–512

    Article  CAS  PubMed  Google Scholar 

  44. Shuldiner AR, O’Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA, 2009,302(8):849–857

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  45. Bouman HJ, Schömig E, van Werkum JW, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med, 2010,17(1):110–116

    Article  PubMed  Google Scholar 

  46. Zou JJ, Xie HG, Chen SL, et al. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention. Eur J Clin Pharmacol, 2013,69(4):771–777

    Article  PubMed  Google Scholar 

  47. Xie X, Ma YT, Yang YN, et al. CYP2C19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients with coronary stent placement in a Chinese population. PLoS One, 2013, 8(3):e59344

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  48. Jeong YH, Tantry US, Kim IS, et al. Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. Circ Cardiovasc Interv, 2011,4(6):585–594

    Article  PubMed  Google Scholar 

  49. Johnson JA, Roden DM, Lesko LJ, et al. Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther, 2012,91(5):774–776

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials, 2007,8(1):16

    Article  PubMed Central  PubMed  Google Scholar 

  51. Anderson JL, Mowere CP, Home BD, et al. Carriage of the CYP2C19*2 allele increases one-year risk of myocardial infarction among recipients of drug-eluting stents treated with clopidogrel. J Am Coll Cardiol, 2009,53(10):A27–A28

    Google Scholar 

  52. Mega JL, Thakuria JV, Cannon CP, et al. Sequence variation in CYP metabolism genes and cardiovascular outcomes following treatment with clopidogrel: insight from the CLARITY-TIMI 28 genomic study. J Am Coll Cardiol, 2008,51(10):A206

    Google Scholar 

  53. Peng Y, Chen M, Liu XJ, et al. The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease. Atherosclerosis, 2013,227(1):106–111

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

    Xuan Niu  (牛 璇), Ling Mao  (毛 玲), Yan Huang  (黄 燕), Suraj Baral  (苏冉杰), Jian-yong Li  (李剑勇), Yuan Gao  (高 原), Yuan-peng Xia  (夏远鹏), Quan-wei He  (贺权威), Meng-die Wang  (王梦嵽), Man Li  (李 嫚) & Bo Hu  (胡 波)

  2. Department of Epidemiology and Biostatistics, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    Li Zou  (邹 丽) & Xiao-ping Miao  (缪小平)

Authors
  1. Xuan Niu  (牛 璇)
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ling Mao  (毛 玲)
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan Huang  (黄 燕)
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Suraj Baral  (苏冉杰)
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jian-yong Li  (李剑勇)
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuan Gao  (高 原)
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yuan-peng Xia  (夏远鹏)
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Quan-wei He  (贺权威)
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Meng-die Wang  (王梦嵽)
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Man Li  (李 嫚)
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Li Zou  (邹 丽)
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Xiao-ping Miao  (缪小平)
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Bo Hu  (胡 波)
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bo Hu  (胡 波).

Additional information

The authors contributed equally to this work.

This project was supported by grants from National Natural Science Foundation of China (Nos. 81371311 and 81101905), and New Century Excellent Talents in University of China (No. NCET-10-0406).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niu, X., Mao, L., Huang, Y. et al. CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis. J. Huazhong Univ. Sci. Technol. [Med. Sci.] 35, 147–156 (2015). https://doi.org/10.1007/s11596-015-1404-7

Download citation

  • Received:

  • Revised:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-015-1404-7

Key words

Search

Navigation